DLVR Therapeutics

DLVR Therapeutics is a biotechnology company co-founded by University Health Network, the Ontario Institute for Cancer Research and MaRS

DLVR Therapeutics is a biotechnology company co-founded by University Health Network, the Ontario Institute for Cancer Research and MaRS Innovation. The company is focused on developing a novel, HDL-like Peptide-Phospholipid Scaffold (HPPS) nanoparticle delivery system which selectively targets lipophilic small molecules and siRNA, initially to cancer cells. The company has two principal programs: the first is focused on improving the therapeutic index of known chemotherapeutic drugs; and, the second is focused on the targeted delivery of siRNA. DLVR intends to enter into drug development collaborations with biopharmaceutical partners for both programs.